DE69620253T2 - N-acylaminoalkylhydrazinecarboximidamide - Google Patents

N-acylaminoalkylhydrazinecarboximidamide

Info

Publication number
DE69620253T2
DE69620253T2 DE69620253T DE69620253T DE69620253T2 DE 69620253 T2 DE69620253 T2 DE 69620253T2 DE 69620253 T DE69620253 T DE 69620253T DE 69620253 T DE69620253 T DE 69620253T DE 69620253 T2 DE69620253 T2 DE 69620253T2
Authority
DE
Germany
Prior art keywords
carbon atoms
composition
group containing
inhibiting
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620253T
Other languages
English (en)
Other versions
DE69620253D1 (en
Inventor
C Ulrich
R Wagle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synvista Therapeutics Inc
Original Assignee
Alteon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/771,959 external-priority patent/US5877217A/en
Application filed by Alteon Inc filed Critical Alteon Inc
Application granted granted Critical
Publication of DE69620253D1 publication Critical patent/DE69620253D1/de
Publication of DE69620253T2 publication Critical patent/DE69620253T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
DE69620253T 1995-12-26 1996-12-26 N-acylaminoalkylhydrazinecarboximidamide Expired - Fee Related DE69620253T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US922095P 1995-12-26 1995-12-26
US61840796A 1996-03-19 1996-03-19
US08/771,959 US5877217A (en) 1995-12-26 1996-12-23 N-acylaminoalkyl-hydrazinecarboximidamides
PCT/US1996/020810 WO1997023447A1 (en) 1995-12-26 1996-12-26 N-acylaminoalkylhydrazinecarboximidamides

Publications (2)

Publication Number Publication Date
DE69620253D1 DE69620253D1 (en) 2002-05-02
DE69620253T2 true DE69620253T2 (de) 2002-09-19

Family

ID=27358809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620253T Expired - Fee Related DE69620253T2 (de) 1995-12-26 1996-12-26 N-acylaminoalkylhydrazinecarboximidamide

Country Status (15)

Country Link
EP (1) EP0888293B1 (de)
JP (1) JP2000502684A (de)
CN (1) CN1209117A (de)
AT (1) ATE215068T1 (de)
AU (1) AU720796B2 (de)
BR (1) BR9612304A (de)
CA (1) CA2241746A1 (de)
DE (1) DE69620253T2 (de)
DK (1) DK0888293T3 (de)
ES (1) ES2174132T3 (de)
NO (1) NO982976L (de)
NZ (1) NZ326238A (de)
PT (1) PT888293E (de)
TW (1) TW502012B (de)
WO (1) WO1997023447A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2731947B1 (de) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolin derivat, dessen herstellung und verwendung in pharmazeutischen zusammensetzungen zur behandlung von typ i und typ ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (de) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (de) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medizinische verwendung eines dpp-4-inhibitors
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging

Also Published As

Publication number Publication date
ES2174132T3 (es) 2002-11-01
WO1997023447A1 (en) 1997-07-03
ATE215068T1 (de) 2002-04-15
NO982976D0 (no) 1998-06-26
DE69620253D1 (en) 2002-05-02
CN1209117A (zh) 1999-02-24
BR9612304A (pt) 1999-07-13
DK0888293T3 (da) 2002-04-22
PT888293E (pt) 2002-07-31
AU1356097A (en) 1997-07-17
JP2000502684A (ja) 2000-03-07
CA2241746A1 (en) 1997-07-03
EP0888293B1 (de) 2002-03-27
NZ326238A (en) 1999-11-29
AU720796B2 (en) 2000-06-15
TW502012B (en) 2002-09-11
EP0888293A1 (de) 1999-01-07
NO982976L (no) 1998-08-26

Similar Documents

Publication Publication Date Title
ATE215068T1 (de) N-acylaminoalkylhydrazinecarboximidamide
ATE112165T1 (de) Verfahren und mittel zur hemmung des proteinveraltens.
WO1993014750A3 (en) Amino acids useful as inhibitors of the advanced glycosylation of proteins
RU94046295A (ru) L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава
NZ312840A (en) Ketoheterocyclic inhibitors of factor Xa
RU94046457A (ru) Производные аспартама, способ их получения и содержащее их подслащивающее средство
HK1039488A1 (en) Tricylic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases.
PT1004578E (pt) Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
MY135057A (en) Dolastatin 15 derivatives
EA199800773A1 (ru) Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы
EA199800378A1 (ru) Новый способ получения фенилимидазолидиновых производных
AU3895689A (en) Cyclic sulfur-containing amino acid derivatives
DE69718775T2 (de) 1,2,4-triazinderivate zur inhibierung der proteinglycosylierung
AU2825897A (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
WO1997042175B1 (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
AU686104B2 (en) Substituted amidinonaphthyl ester derivatives
BR8303032A (pt) Sililoxialcano-azois, processo para sua preparacao, composicoes praguicidas, processo para o combate ou protecao de uma infestacao por microorganismo e processo para a preparacao de uma composicao
BR9604914A (pt) Inibidores de agregaçao de plaquetas contendo resíduos de aminoácido de cadeia lateral aminérgicos c-terminais
ATE220544T1 (de) Neue verwendung von pyrazolopyridinverbindungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee